Anticancer drugs are the first cause of drug-induced liver injury in a reference hospital.

dc.contributor.authorLens García, Sabela
dc.contributor.authorLondoño, María Carlota
dc.contributor.authorForns, Xavier
dc.contributor.authorPocurull Aparicio, Anna
dc.contributor.authorMoreta, Maria José
dc.contributor.authorHeitman, David
dc.contributor.authorOlivas, Ignasi
dc.contributor.authorCollazos Clemente, Cristina
dc.contributor.authorCanga, Elia
dc.contributor.authorSáez Peñataro, Joaquín
dc.contributor.authorAndrade, Raúl J.
dc.contributor.authorLucena, M. Isabel
dc.contributor.authorMariño Méndez, Zoe
dc.contributor.authorDiaz Lorca, Maria Alba
dc.date.accessioned2026-02-27T15:33:48Z
dc.date.available2026-02-27T15:33:48Z
dc.date.issued2024-02
dc.date.updated2026-02-27T15:33:48Z
dc.description.abstractDrug-induced liver injury (DILI) is a challenging liver disorder for hepatologists. We aimed to assess the pattern and causes of DILI in a tertiary hospital. We registered prospectively all patients referred with suspicion of DILI from 2018 to 2023. A total of 106 patients fulfilled the diagnostic criteria (30 caused by paracetamol were excluded; total number 76). The pattern of liver injury was hepatocellular in 55 (72%). Drugs causing DILI were antineoplastic (26%), antibiotics (24%), analgesics (12%), and recreational drugs (9%). Regarding clinical outcomes, 39 (51%) required hospitalization and 7 (9%) underwent a liver transplantation or died from acute liver injury. We identified 126 additional patients with DILI due to immune check-point inhibitors who were not referred to a liver disease specialist. Antineoplastic drugs have become the first cause of DILI in hospitals. A multidisciplinary approach and specific educational tools to increase DILI awareness are needed among different specialists.
dc.format.extent15 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec750004
dc.identifier.idimarina9380430
dc.identifier.issn1478-3223
dc.identifier.pmid38131512
dc.identifier.urihttps://hdl.handle.net/2445/227686
dc.language.isoeng
dc.publisherJohn Wiley & Sons
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1111/liv.15821
dc.relation.ispartofLiver International, 2024, vol. 44, num.2, p. 286-292
dc.relation.urihttps://doi.org/10.1111/liv.15821
dc.rights(c) John Wiley & Sons, 2023
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.subject.classificationToxicitat dels medicaments
dc.subject.classificationMalalties del fetge
dc.subject.classificationMedicaments antineoplàstics
dc.subject.otherDrug toxicity
dc.subject.otherLiver diseases
dc.subject.otherAntineoplastic agents
dc.titleAnticancer drugs are the first cause of drug-induced liver injury in a reference hospital.
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
864998.pdf
Mida:
462.12 KB
Format:
Adobe Portable Document Format